Kelfred Holdings Valuation

Is 1134 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1134 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1134's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1134's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1134?

Key metric: As 1134 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1134. This is calculated by dividing 1134's market cap by their current revenue.
What is 1134's PS Ratio?
PS Ratio	0.3x
Sales	HK$395.61m
Market Cap	HK$125.00m

1134 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	-5.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 1134's PS Ratio compare to its peers?

The above table shows the PS ratio for 1134 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1x
876 Kaisa Health Group Holdings	0.7x	n/a	HK$126.1m
8622 Huakang Biomedical Holdings	3x	n/a	HK$80.1m
2393 Yestar Healthcare Holdings	0.06x	n/a	HK$167.9m
1120 Arts Optical International Holdings	0.3x	n/a	HK$320.6m
1134 Kelfred Holdings	0.3x	n/a	HK$125.0m

Price-To-Sales vs Peers: 1134 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does 1134's PS Ratio compare vs other companies in the HK Medical Equipment Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	3.3x	23.0%
1134 Kelfred Holdings	0.3x	n/a	US$16.06m
1763 China Isotope & Radiation	0.5x	n/a	US$437.35m
1120 Arts Optical International Holdings	0.3x	n/a	US$41.20m

5 Companies		Estimated Growth	Market Cap
Industry Avg.	3.3x	40.3%
1134 Kelfred Holdings	0.3x	n/a	US$16.06m

No more companies

Price-To-Sales vs Industry: 1134 is good value based on its Price-To-Sales Ratio (0.3x) compared to the Hong Kong Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is 1134's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1134 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1134's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hygeia Healthcare Holdings

HK$9.8b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$15.80

-11.3%

-67.2%

Sinopharm Group

HK$62.7b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.10

-2.2%

3.7%